Dofetilide: a new class III antiarrhythmic agent

@article{Roukoz2007DofetilideAN,
  title={Dofetilide: a new class III antiarrhythmic agent},
  author={Henri Roukoz and Walid I. Saliba},
  journal={Expert Review of Cardiovascular Therapy},
  year={2007},
  volume={5},
  pages={19 - 9}
}
  • H. Roukoz, W. Saliba
  • Published 1 January 2007
  • Medicine
  • Expert Review of Cardiovascular Therapy
Dofetilide is a relatively new class III antiarrhythmic agent that selectively blocks the rapid component of the cardiac ion channel delayed rectifier current. This results in an increase in the action potential duration and effective refractory period of the myocyte, thereby terminating reentrant tachyarrhythmias and preventing their re-induction. Oral dofetilide is effective in the conversion of atrial fibrillation and flutter to sinus rhythm and in the maintenance of sinus rhythm after… Expand
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
TLDR
The main new generation class III drugs are: dofetilide, dronedarone, azimilide, and ibutilide, which are the gold standard in the prevention of recurrence of atrial fibrillation and flutter. Expand
Newer Antiarrhythmic Agents for Atrial Fibrillation: Shall we Eventually do away with Proarrhythmia?
TLDR
Future antiarrhythmic agents will probably be atrial-selective blocking agents without affecting repolarization in the ventricular myocardium and thus avoid ventricular proarrhythmics with its attendant life-threatening consequences. Expand
Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
TLDR
The underlying mechanism, risk factors and precautionary measures to avoid dofetilide induced QT prolongation and ventricular tachycardia/Tdp are discussed and a scheme for the management of QT prolongedation, ventricular arrhythmia and Tdp is suggested. Expand
Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses
TLDR
The combination of dofetilide and ranolazine showed increased antiarrhythmic effects on acutely induced AF in horses, affecting time to cardioversion, AF vulnerability, and AF duration. Expand
Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
TLDR
D should be considered a pharmacologic alternative when adult patients with CHD develop AT but needs close monitoring for potential ventricular pro-arrhythmia. Expand
Usefulness of dofetilide for the prevention of atrial tachyarrhythmias (atrial fibrillation or flutter) after coronary artery bypass grafting.
TLDR
In conclusion, perioperative dofetilide can decrease both the incidence of POAT and LOS in a safe manner. Expand
Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option
TLDR
The DOxapram Conversion TO Sinus rhythm (DOCTOS)-Trial will reveal whether doxaprams, a potent TASK-1 inhibitor, can be used for acute cardioversion of persistent and paroxysmal AF in patients, potentially leading to a new treatment option for AF. Expand
Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter
TLDR
Dofetilide is more effective in patients with persistent than in those with paroxysmal AF/AFL, and short-term response does not necessarily predict long-term efficacy. Expand
Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin
TLDR
This study demonstrates synergistic antiarrhythmic benefits of combined block of IKur and INa, as well as those of INa and combined multi K+-current block of acacetin, without significant alterations of ventricular repolarization and QT intervals. Expand
Dofetilide-Induced Microvolt T-Wave Alternans
TLDR
In healthy subjects, dofetilide increases occurrence and levels (6 times baseline value on average) of TWA in the hours following its administration, and inhealthy subjects, this phenomenon is associated to malignant ventricular arrhythmias. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 71 REFERENCES
Azimilide dihydrochloride, a novel antiarrhythmic agent.
TLDR
Preclinical and clinical studies indicate that azimilide prolongs cardiac refractory period in a dose-dependent manner, as manifested by increases in action potential duration, QTc interval, and effective refractor period. Expand
Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
TLDR
Intravenous dofetilide can convert sustained atrial fibrillation or flutter to sinus rhythm, however, its efficacy is greater in flutter--a response that contrasts with the poorer response seen with class I agents. Expand
Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.
TLDR
This open study evaluated the acute electrophysiologic effects, antiarrhythmic efficacy, and safety of different doses of intravenous dofetilide, a new class III drug, in 50 patients with sustained monomorphic ventricular tachycardia inducible by programmed electrical stimulation who had previously been unsuccessfully treated with 0 to 7 other drugs. Expand
Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris.
TLDR
The selective prolongation of the refractory periods in both atrium and ventricle, combined with a lack of effect on cardiac conduction parameters, indicates that this drug could be useful in the treatment of both atrial and ventricular reentrant tachyarrhythmias and fibrillation. Expand
Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias.
TLDR
The results imply that the suppression of the development and maintenance of reentrant arrhythmias may result from the lengthening effect of dofetilide on the refractoriness and the consequent elimination of the excitable gap at the critical part of theReentrant loop. Expand
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial
TLDR
Intravenous dofetilide is effective in acute termination of atrial fibrillation and AFL of medium duration, with a particularly high efficacy rate in AFL. Expand
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
TLDR
Intravenous dofetilide is effective in acute termination of AF and AFL of medium duration, with a particularly high efficacy rate in AFL, and a small but serious risk of proarrhythmia must be anticipated. Expand
Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure.
TLDR
In an acute setting, compared with intravenous amiodarone, intravenous dofetilide preserves cardiac function offering a hemodynamic advantage to treat arrhythmias in patients with impaired left ventricular function. Expand
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
TLDR
In patients with congestive heart failure and reduced left ventricular function, dofetilide was effective in converting atrial fibrillation, preventing its recurrence, and reducing the risk of hospitalization for worsening heart failure. Expand
Atrial fibrillation and atrial flutter.
The epidemiology, pathophysiology, diagnosis, evaluation, and treatment of atrial fibrillation (AF) and atrial flutter (AFl) are reviewed, and recent developments and controversies in the approach toExpand
...
1
2
3
4
5
...